Capsugel, continuing its recent expansion in the drug capsule manufacturing arena, this week launched its new platform Lipidex, which the company says offers greater stability and potency for oral drugs.
Teva Pharmaceuticals bought drug delivery company MicroDose Therapeutx this week, taking hold of its inhalation platforms for lung diseases.
Over the next three years the pharma company plans to build a $500 million complex on an 11-acre site at the Cambridge BioMedical Campus.
As medical device companies the world over race to develop an artificial pancreas, the Juvenile Diabetes Research Foundation has teamed up with Becton Dickinson to combine insulin infusion with continuous glucose monitoring and improve the lives of diabetics.
With rates of oral cancer linked to HPV infection on the rise, a group of investigators has pinned down a new biomarker that can be used to identify high-risk patients.
ViroPharma's pipeline of drugs for rare diseases has reportedly stirred the interest of several pharma companies. And once word of the buyout buzz spread, the Exton, PA-based biotech's shares zoomed up 9% yesterday afternoon.
Over the next three years the pharma company plans to build a $500 million complex on its new campus that will house its U.K. operations for biologics and small molecule research as well as the corporate staff now operating in London.
As Siemens banks on personalized medicine to help turn around its healthcare business, the technology giant said its new companion diagnostics deal with Johnson & Johnson is a step in the right direction.
Thanks to some big-name deals over the past year, Ambrx could rake in nearly $1 billion in licensing for its antibody drug conjugates, but the company hasn't lost sight of its in-house development, now partnering with WuXi PharmaTech and a Chinese drugmaker to advance a breast cancer treatment.
Index Ventures recently completed an $11 million Series A investment in XO1, an asset-centric company established with the sole objective of developing the monoclonal antibody ichorcumab under license from Cambridge University.